The oral TLR7 agonist GS-9620 has anti-viral effects in woodchuck and chimpanzee models of chronic hepatitis B virus (HBV) infection. We investigated in a clinical trial the capacity of this agent to reconstitute protective immunity in patients with chronic HBV infection.